Xenon Pharmaceuticals reports Q3 2026 loss, submits NDA for azetukalner and outlines pipeline milestones
Xenon Pharmaceuticals announced third‑quarter 2026 results showing a net loss of $110.4 million, or $1.11 per share, widening 21% from a year earlier. Revenue missed forecasts and R&D expenses rose to $95.6 million. The company submitted a New Drug Application to the FDA for azetukalner in focal seizures, completed enrollment in its Phase 3 X‑NOVA2 depression study, and expects topline data in December 2026. It also reported a cash balance of about $1.15 billion, which management says will fund operations into 2029.
Why it matters
The widened loss and revenue miss pressured the stock, which fell 2.4% in after‑hours trading (the company’s stock impact). However, the NDA submission and strong cash runway give the company the financial flexibility to continue advancing its epilepsy, neuropsychiatry and pain programs through 2029, according to management.
Key facts
- 1Net loss was $110.4 million, or $1.11 per share, a 21% increase versus the same quarter a year earlier. investing.com
- 2Revenue fell slightly short of analyst forecasts. investing.com
- 3Research and development expenses were $95.6 million, up from $77.1 million a year earlier. investing.com
- 4The company submitted an NDA for azetukalner in focal seizures to the FDA in September 2026. rttnews.com
- 5Topline results from the Phase 3 X‑NOVA2 study in major depressive disorder are expected in December 2026. rttnews.com
- 6Cash, cash equivalents and marketable securities totaled $1.1535 billion as of September 30, 2026, expected to fund operations into 2029. rttnews.com
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.